Consideration of antibody drug conjugates development and regulation / 药学学报
Acta Pharmaceutica Sinica
;
(12): 1971-1977, 2020.
Article
in Chinese
| WPRIM
| ID: wpr-825175
ABSTRACT
Antibody drug conjugates (ADCs), as they combine the targetability of monoclonal antibody and cytotoxicity of small molecules, are a growing class of therapeutics for cancer. The key factor of ADCs development is the accurate selection of parameters including tumor target, monoclonal antibody, cytotoxic payload, and linkage strategy of antibody to payload. Here, we summarize the main elements in the structural design and the development of ADCs, as well as the regulatory consideration of product manufacturing and control, which would be helpful for the research and development of ADCs.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Acta Pharmaceutica Sinica
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS